Menu Search
Equities

Hisamitsu Pharmaceutical Co Inc

4530:TYO

Hisamitsu Pharmaceutical Co Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,277.00
  • Today's Change-7.00 / -0.16%
  • Shares traded91.70k
  • 1 Year change-6.84%
  • Beta0.8755
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Feb 29 2024202420232022
OPERATIONS
Net income19,18616,11312,956
Depreciation/depletion5,1104,9524,321
Non-Cash items(4114)(3803)(2814)
Cash taxes paid, supplemental4,0175,333505
Cash interest paid, supplemental181520
Changes in working capital(2057)(4534)4,736
Total cash from operations18,18712,72819,199
INVESTING
Capital expenditures(13036)(7908)(4193)
Other investing and cash flow items, total10,524(15960)(8867)
Total cash from investing(2512)(23868)(13060)
FINANCING
Financing cash flow items(247)(203)(190)
Total cash dividends paid(6578)(6719)(6839)
Issuance (retirement) of stock, net(9796)(7694)(8043)
Issuance (retirement) of debt, net(70)(71)(117)
Total cash from financing(16691)(14687)(15189)
NET CHANGE IN CASH
Foreign exchange effects1,9575,0053,944
Net change in cash941(20822)(5106)
Net cash-begin balance/reserved for future use65,42486,24791,354
Net cash-end balance/reserved for future use66,36665,42486,247
SUPPLEMENTAL INCOME
Depreciation, supplemental5,1104,9524,321
Cash interest paid, supplemental181520
Cash taxes paid, supplemental4,0175,333505
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.